Today

Agents

Chat

Arena

Discover

More

App

Neuropace cuts target price to $14 from $18

NPCE•2026-11-13

KeyBanc cut its target price for Neuropace to $14 from $18.

Related News

Jade Biosciences Q3 net loss widens less than expected

JBIO•2026-11-13

Triple Flag renews buyback program for up to 5% of outstanding shares

TFPM•2026-11-13

Bilibili converts 3,867,337 Class Y shares to Class Z shares

BILI•2026-11-13

Nucor announces dividend of R$ 0.1772032220 per BDR

NUE•2026-11-13

Hanover Insurance CEO John C. Roche reports disposal of $18.56 million in common shares

THG•2026-11-13

Neuropace cuts target price to $14 from $18 - NPCE News | Rallies